## Kye Young Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9425374/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 213-222.	10.7	1,740
2	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology, The, 2015, 16, 141-151.	10.7	1,369
3	FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2014, 140, 89-98.	2.5	88
4	Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer, 2012, 75, 321-325.	2.0	70
5	Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA. BMC Cancer, 2018, 18, 1236.	2.6	65
6	Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients. Molecular Cancer, 2018, 17, 15.	19.2	57
7	The performance of a novel amino acid multivariate index for detecting lung cancer: A case control study in Korea. Lung Cancer, 2015, 90, 522-527.	2.0	43
8	Extracellular vesicle-based EGFR genotyping in bronchoalveolar lavage fluid from treatment-naive non-small cell lung cancer patients. Translational Lung Cancer Research, 2019, 8, 1051-1060.	2.8	35
9	The Korean guideline for lung cancer screening. Journal of the Korean Medical Association, 2015, 58, 291.	0.3	32
10	Targeted Next-Generation Sequencing Analysis for Recurrence in Early-Stage Lung Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 3983-3993.	1.5	26
11	Characteristics and Clinical Application of Extracellular Vesicle-Derived DNA. Cancers, 2021, 13, 3827.	3.7	22
12	Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial. Clinical Lung Cancer, 2017, 18, e289-e296.	2.6	21
13	Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment. Lung Cancer, 2014, 83, 252-258.	2.0	18
14	Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study. BMC Cancer, 2018, 18, 768.	2.6	18
15	Liquid biopsy using extracellular vesicle–derived DNA in lung adenocarcinoma. Journal of Pathology and Translational Medicine, 2020, 54, 453-461.	1.1	16
16	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clinical Cancer Research, 2022, 28, 2286-2296.	7.0	14
17	Genomic profiling of extracellular vesicle-derived DNA from bronchoalveolar lavage fluid of patients with lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 104-116.	2.8	13
18	Clinical features of lung adenocarcinomas with epidermal growth factor receptor mutations and miliary disseminated carcinomatosis. Thoracic Cancer, 2015, 6, 629-635.	1.9	12

Kye Young Lee

#	Article	IF	CITATIONS
19	Detection of <i>EGFR</i> and <i>KRAS</i> Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer. Journal of Korean Medical Science, 2016, 31, 1224.	2.5	9
20	Extracellular Vesicle-Based Bronchoalveolar Lavage Fluid Liquid Biopsy for EGFR Mutation Testing in Advanced Non-Squamous NSCLC. Cancers, 2022, 14, 2744.	3.7	9
21	A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient. Journal of Thoracic Oncology, 2017, 12, e179-e181.	1.1	3
22	Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring EGFR Mutations. Cancers, 2021, 13, 3632.	3.7	3
23	ASO Author Reflections: CTNNB1 and Fusion Genes as Predictors for Recurrence in Resected Early-Stage Lung Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 3994-3995.	1.5	2